comprehensive -WSS

comprehensive

author：entertainment 2025-09-06 03:11:15 Page View：1651

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In search for therapies for solid tumors, companies turn to claudin
Next article： Malaria cases in Florida and Texas: Here’s what you need to know

comprehensive

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

AdobeSometimes,anappleadayreallyisjustwhatthedoctorordered.Andforthepastseveralyears,organizationsli

ALS groups 'won't be played again' by the FDA, drug sponsors

MattScozzariholdshisgirlfriendSabrinaParker'shandduringafriendshipceremonyinJacksonville,N.C.,inNove

The high cost of giving birth even with insurance

AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

A Q&A with Aletha Maybank, AMA’s chief health equity officer

AlexHogan/STATIntheaftermathofthepolicemurderofGeorgeFloydandsubsequentBlackLivesMatterprotestsacros

comprehensive

knowledge

comprehensive

A Q&A with Aletha Maybank, AMA’s chief health equity officer